SCHEMBL23364326

SCHEMBL23364326

COc1cc2c(cc1OC)C1(CC1)N(c1ccnc(-c3ncccn3)n1)C2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.38
CYP3A4 P08684 4/20 0.38
CYP2D6 P10635 3/20 0.38
CYP2C19 P33261 3/20 0.38
ALDH1A1 P00352 3/20 0.38
USP2 O75604 1/20 0.38
KDM4E B2RXH2 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
PARP1 P09874 1/20 0.34
PDCD1 Q15116 2/20 0.34
CD274 Q9NZQ7 2/20 0.34
AVPR1A P37288 1/20 0.34
HTR2A P28223 1/20 0.34
HSD17B10 Q99714 3/20 0.33
TP53 P04637 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24911670 0.92 ALDH1A1 (0.38) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL23364315 0.74 ALDH1A1 (0.45) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL30125272 0.74 ALDH1A1 (0.45) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL23364322 0.72 MEN1 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL30125500 0.72 MEN1 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL24910706 0.72 KDM4E (0.40) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL24910673 0.70 KDM4E (0.41) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL23364299 0.70 KDM4E (0.41) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL23364264 0.70 KDM4E (0.41) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL23365335 0.68 KDM4E (0.37) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 US disclosed
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 US disclosed
WO-2021097075-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, CDV3, HCCS CYP1A2 949/4885CYP3A4 182/4885CYP2D6 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.